Nuvation Bio Inc. cash flow to debt ratio of -1.71K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Nuvation Bio Inc.'s free cash flow has decreased 33.09% from $-130.57M last year to $-173.78M, signaling decreasing performance

Nuvation Bio Inc.'s debt to equity ratio is 0.03, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Nuvation Bio Inc.'s debt has increased relative to shareholder equity from 0.02 last year to 0.03 today, signaling weakened financials

Nuvation Bio Inc. has negative EBITDA, making leverage ratio unreliable

Nuvation Bio Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Nuvation Bio Inc.'s profit margin has increased (-98.59%) in the last year from -7.21K% to -102.06%, signaling increasing performance

Nuvation Bio Inc.'s short-term assets of $571.52M exceed its short-term liabilities of $82.23M

Nuvation Bio Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Nuvation Bio Inc.'s return on equity of -44.10%, is lower than 15.00%, indicating bad performance

Nuvation Bio Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Nuvation Bio Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Nuvation Bio Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Nuvation Bio Inc. has negative free cash flow, indicating cash burn

Nuvation Bio Inc.'s yearly earnings has increased -63.97% since last year from $-567.94M to $-204.63M, signaling increasing performance

Nuvation Bio Inc.'s yearly revenue has increased 698.96% since last year from $7.87M to $62.90M, signaling increasing performance

ROIC -27.90% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Nuvation Bio Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Nuvation Bio Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Nuvation Bio Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Nuvation Bio Inc. has insufficient data to evaluate this check.

Nuvation Bio Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Nuvation Bio Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Nuvation Bio Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Nuvation Bio Inc. has insufficient data to evaluate this check.

Nuvation Bio Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Nuvation Bio Inc. has a price-to-book ratio of 6.14x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Nuvation Bio Inc. has a price-to-sales ratio of 13.71x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue